Placebo to MK-8527

Phase 3

Placebo to MK-8527 is one of 6 therapeutic programs targeting Human Immunodeficiency Virus (HIV). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Human Immunodeficiency Virus (HIV)Recruiting

Human Immunodeficiency Virus (HIV)Phase 3

Recruiting

Competition

Competitive Landscape

9 competitors in Human Immunodeficiency Virus (HIV)

#DrugCompanyPhaseTrials

FTC/TDF

Gilead

Phase 3

2 2

MK-8527

Merck & Co.

Phase 3

3 3

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 4

Rifadin

Sanofi

Phase 1

1 5

Placebo to MK-8527

Merck & Co.

Phase 3

1 6

DOR/3TC/TDF

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Human Immunodeficiency Virus (HIV)

NCT07044297

Clinical

Trials by Indication[1]

Human Immunodeficiency Virus (HIV)1 trial

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07044297·4,390 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo to MK-8527. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo to MK-8527. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Merck & Co.

Placebo to MK-8527

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Human Immunodeficiency Virus (HIV)1 trial

References

Drug Info

Quick Facts

Related News